Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.60 |
| ▸ | CA3 | P07451 | 3/20 | 0.60 |
| ▸ | CA4 | P22748 | 3/20 | 0.60 |
| ▸ | CA6 | P23280 | 3/20 | 0.60 |
| ▸ | CA5A | P35218 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164063 | 0.89 | CA1 (0.72) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11558350 | 0.80 | CA9 (0.60) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11247493 | 0.80 | ALDH1A1 (0.73) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL8087428 | 0.80 | POLB (0.76) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL8094050 | 0.80 | POLB (0.76) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL44366 | 0.80 | POLB (0.76) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4687773 | 0.77 | CA1 (0.56) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4689723 | 0.77 | CA1 (0.63) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL18029396 | 0.76 | CA9 (0.64) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4349260 | 0.76 | CA12 (0.50) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | ALDH1A1 873/4885CA12 4487/4885CA1 3406/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | ALDH1A1 2564/4885CA12 3393/4885CA1 1241/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | ALDH1A1 2682/4885CA12 3792/4885CA1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.